DIA: Driving Insights to Action

Has Joining ICH Accelerated Innovation in China?

May 1, 2019

“China joining ICH is a magnificent milestone for the pharmaceutical industry in China,” explains Dr. Jingsong Wang, Chairman and Chief Executive Officer of Harbour Biomed. “We can see clearly more and more local pharmaceutical companies adopting the international standards to have a more innovative portfolio to face the competition from their global partners or counterparts.” Dr. Wang serves on the Steering Committee for our DIA China 2019 Annual Meeting in Beijing.